CDK4/6-IN-28 是一种高效、口服有效且具有选择性的 CDK4/6 抑制剂,其 IC50 值分别为 14.02 和 10.03 nM,可抑制乳腺癌细胞的集落形成、迁移与增殖,诱导乳腺癌细胞发生 G1 期细胞周期阻滞及细胞凋亡 (apoptosis),在乳腺癌异种移植小鼠模型中表现出肿瘤抑制活性,可用于乳腺癌相关研究。
产品编号: MS-R63761 CAS No.: 3110098-09-1 分子式: C25H29N7 分子量: 427.54
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

CDK4/6-IN-28 是一种高效、口服有效且具有选择性的 CDK4/6 抑制剂,其 IC50 值分别为 14.02 和 10.03 nM,可抑制乳腺癌细胞的集落形成、迁移与增殖,诱导乳腺癌细胞发生 G1 期细胞周期阻滞及细胞凋亡 (apoptosis),在乳腺癌异种移植小鼠模型中表现出肿瘤抑制活性,可用于乳腺癌相关研究。

生物实验数据

生物活性 CDK4/6-IN-28 is a potent, orally active, and selective CDK4/6 inhibitor with IC50 values of 14.02 and 10.03 nM, respectively, which inhibits colony formation, migration, and proliferation of breast cancer cells, induces G1 cell cycle arrest and apoptosis (apoptosis) in breast cancer cells, exhibits tumor suppressive activity in breast cancer xenograft mouse models, and can be used for breast cancer-related research.
IC50 & Target

CDK6

10.03 nM (IC50)

CDK4

14.02 nM (IC50)

BCL2

 

Caspase 3

 

体外研究
(In Vitro)

CDK4/6-IN-28 (compound 3c) (72 h) 可强效抑制 MCF-7、4T1 和 MDA-MB-231 细胞的增殖,其 IC50 值分别为 0.11、0.21 和 0.12 μM,且相对于非癌细胞 3T3 细胞具有良好的选择性 (IC50 = 4.64 μM)。
CDK4/6-IN-28 (1-2 μM; 7 days) 以浓度依赖的方式抑制 MCF-7 乳腺癌细胞的集落形成。
CDK4/6-IN-28 (1-2 μM; 24 h) 可呈浓度依赖性抑制 MCF-7 乳腺癌细胞的迁移能力。
CDK4/6-IN-28 (1-2 μM; 12-24 h) 可诱导 MCF-7 乳腺癌细胞发生细胞凋亡,降低线粒体膜电位,并以浓度依赖的方式增加 ROS 的生成。
CDK4/6-IN-28 (1-2 μM; 24 h) 可在 MCF-7 乳腺癌细胞中诱导浓度依赖性的 G1 期细胞周期阻滞。
CDK4/6-IN-28 (1-4 μM; 24 h) 以浓度依赖的方式阻断 MCF-7 乳腺癌细胞中的 CDK4/6-Rb-E2F 信号通路。

Cell Proliferation Assay

Cell Line: MCF-7 breast cancer cells
Concentration: 1, 2 μM
Incubation Time: 7 days
Result: Reduced both colony number and size in a concentration-dependent manner compared to control.
Showed inhibitory efficacy comparable to positive control Abemaciclib (MS-E06526) at 2 μM.

Cell Migration Assay

Cell Line: MCF-7 breast cancer cells
Concentration: 1, 2 μM
Incubation Time: 24 h
Result: Suppressed MCF-7 cell migration in a concentration-dependent manner, as shown by impaired wound closure compared to control.
Showed anti-migratory efficacy comparable to positive control Abemaciclib at 2 μM.

Apoptosis Analysis

Cell Line: MCF-7 breast cancer cells
Concentration: 1, 2 μM
Incubation Time: 12 h
Result: Induced concentration-dependent apoptotic features including nuclear condensation, chromatin condensation, and apoptotic body formation.
Caused a concentration-dependent decrease in red JC-1 fluorescence and increase in green fluorescence, with effect comparable to Abemaciclib at 2 μM.

Cell Cycle Analysis

Cell Line: MCF-7 breast cancer cells
Concentration: 1, 2 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent increase in the proportion of MCF-7 cells in the G1 phase, with 2 μM resulting in 65.13% of cells in G1.
Induced concentration-dependent apoptosis, with 1 μM causing a total apoptosis rate of 13.36% and 2 μM causing a total apoptosis rate of 19.14%.

Western Blot Analysis

Cell Line: MCF-7 breast cancer cells
Concentration: 1, 2, 4 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent decrease in phosphorylated Rb (p-Rb) levels.
Downregulated total Rb, E2F1, and Cyclin-D1 expression in a concentration-dependent manner.
Showed inhibitory effects on p-Rb and E2F1 expression comparable to 4 μM Abemaciclib at 4 μM.
体内研究
(In Vivo)

CDK4/6-IN-28 (compound 3c) (25-50 mg/kg;口服;每隔 1 天给药 1 次;共 14 天) 可抑制 MCF-7 异种移植小鼠的肿瘤生长。
CDK4/6-IN-28 (60-120 mg/kg;口服;每日一次;连续 7 天) 在健康 KM 小鼠中展现出良好的安全性。

Animal Model: BALB/c-nu nude mice (female, 4-6 weeks old, 18-20 g) injected with MCF-7 cells
Dosage: 25; 50 mg/kg
Administration: p.o.; every other day; 14 days
Result: Achieved a tumor inhibition rate of 30.41% at 25 mg/kg.
Achieved a tumor inhibition rate of 45.20% at 50 mg/kg.
Maintained stable body weight throughout treatment.
Showed no significant differences in total protein, ALT, lactate dehydrogenase, or urea levels compared to control; AST and creatinine levels were slightly lower than control, while alkaline phosphatase levels were slightly higher.
Showed no significant tissue damage to heart, liver, spleen, lung, or kidney via HE staining.
Induced dose-dependent decreases in Bcl2, Ki67, and PCNA expression, and increases in Caspase3 expression.
Animal Model: KM mice (female, 4-5 weeks old, 18-22 g)
Dosage: 60; 120 mg/kg
Administration: p.o.; daily; 7 days
Result: Increased alanine aminotransferase (ALT) levels from 100 U/L to 111.67 U/L, and aspartate aminotransferase (AST) levels from 40.67 U/L to 46 U/L at 120 mg/kg, with both values remaining within physiological reference ranges and ALT/AST ratios below 2.6.
Showed extremely mild cellular degeneration and edema in liver and kidney at 120 mg/kg, with no severe damage to heart, lung, or spleen.

化学信息

分子量 427.54
分子式 C25H29N7
CAS No. 3110098-09-1

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础